These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38424537)

  • 1. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.
    Kwan ATH; Le GH; Guo Z; Ceban F; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
    Ann Gen Psychiatry; 2024 Feb; 23(1):10. PubMed ID: 38424537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine.
    Kwan ATH; Guo Z; Ceban F; Le GH; Wong S; Teopiz KM; Rhee TG; Ho R; Di Vincenzo JD; Badulescu S; Meshkat S; Cao B; Rosenblat JD; d'Andrea G; Dev DA; Phan L; Subramaniapillai M; McIntyre RS
    Adv Ther; 2024 May; 41(5):1983-1994. PubMed ID: 38520501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.
    McIntyre RS; Phan L; Kwan ATH; Mansur RB; Rosenblat JD; Guo Z; Le GH; Lui LMW; Teopiz KM; Ceban F; Lee Y; Bailey J; Ramachandra R; Di Vincenzo J; Badulescu S; Gill H; Drzadzewski P; Subramaniapillai M
    Brain; 2024 Mar; 147(3):849-857. PubMed ID: 37936330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of elevated body mass index (BMI) on cognitive functioning and inflammation in persons with post-COVID-19 condition: a secondary analysis.
    Le GH; Kwan ATH; Guo Z; Wong S; Badulescu S; Gill H; Teopiz KM; Meshkat S; Ceban F; Phan L; Subramaniapillai M; Di Vincenzo JD; Rosenblat JD; Mansur RB; d'Andrea G; Ho R; Rhee TG; McIntyre RS
    Acta Neuropsychiatr; 2024 Apr; ():1-7. PubMed ID: 38605630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis.
    Le GH; Kwan ATH; Wong S; Guo Z; Teopiz KM; Badulescu S; Meshkat S; d'Andrea G; Ho R; Rhee TG; Cao B; Phan L; Rosenblat JD; Mansur RB; Subramaniapillai M; McIntyre RS
    Adv Ther; 2024 Feb; 41(2):686-695. PubMed ID: 38114867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis.
    Teopiz KM; Kwan ATH; Le GH; Guo Z; Badulescu S; Ceban F; Meshkat S; Di Vincenzo JD; d'Andrea G; Cao B; Ho R; Rhee TG; Dev DA; Phan L; Subramaniapillai M; Mansur RB; Rosenblat JD; McIntyre RS
    Curr Med Res Opin; 2024 Jul; 40(7):1203-1209. PubMed ID: 38860901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater Role of Cognitive Impairment Over Fatigue in Post-COVID-19 Quality of Life: A Post-Hoc Analysis of a Randomized Controlled Trial.
    Kwan ATH; Lakhani M; Le GH; Singh G; Teopiz KM; Guo Z; Ceban F; Dhaliwal KK; Badulescu S; Ho R; Rhee TG; Cao B; d'Andrea G; McIntyre RS
    medRxiv; 2024 Mar; ():. PubMed ID: 38562760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials.
    McIntyre RS; Harrison J; Loft H; Jacobson W; Olsen CK
    Int J Neuropsychopharmacol; 2016 Jun; 19(10):. PubMed ID: 27312740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults.
    McIntyre RS; Lophaven S; Olsen CK
    Int J Neuropsychopharmacol; 2014 Oct; 17(10):1557-67. PubMed ID: 24787143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.
    Badulescu S; Le GH; Wong S; Kwan ATH; Guo Z; Teopiz KM; Phan L; Subramaniapillai M; Rosenblat JD; Mansur RB; McIntyre RS
    Neurol Sci; 2024 Apr; 45(4):1335-1342. PubMed ID: 38321333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which Cognitive Domains are Improved by Treatment with Vortioxetine?
    Harrison JE; Lophaven S; Olsen CK
    Int J Neuropsychopharmacol; 2016 May; 19(10):. PubMed ID: 27231256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory Analysis of the Effects of Celecoxib on Cognitive Function in Vortioxetine-Treated Patients With Major Depressive Disorder in the PREDDICT Study: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Sampson E; Mills NT; Hori H; Schwarte K; Hohoff C; Schubert O; Clark SR; Fourrier C; Baune BT
    J Clin Psychiatry; 2023 Oct; 84(6):. PubMed ID: 37796652
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between anhedonia and psychosocial functioning in post-COVID-19 condition: a
    Liao S; Teopiz KM; Kwan ATH; Le GH; Wong S; Ballum H; Rhee TG; Badulescu S; Cao B; Guo Z; Meshkat S; Phan L; Subramaniapillai M; Ho R; McIntyre RS
    Curr Med Res Opin; 2024 Jul; ():1-5. PubMed ID: 38954402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine.
    Nierenberg AA; Loft H; Olsen CK
    J Affect Disord; 2019 May; 250():35-42. PubMed ID: 30826492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder.
    Inoue T; Sasai K; Kitagawa T; Nishimura A; Inada I
    Psychiatry Clin Neurosci; 2020 Feb; 74(2):140-148. PubMed ID: 31725942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, placebo-controlled study of the efficacy and safety of vortioxetine 10 mg and 20 mg in adults with major depressive disorder.
    Jacobsen PL; Mahableshwarkar AR; Serenko M; Chan S; Trivedi MH
    J Clin Psychiatry; 2015 May; 76(5):575-82. PubMed ID: 26035185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of Baseline Anxiety on Well-being in People with Post-COVID-19 Condition: A Secondary Analysis.
    Kleine N; Kwan ATH; Le GH; Guo Z; Phan L; Subramaniapillai M; McIntyre RS
    CNS Spectr; 2024 Apr; 29(2):150-154. PubMed ID: 38453677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.